Primary Risk Drivers
Below is a snapshot of domains that materially influence the MARA Rating.
Clinical effectiveness
Entrectinib shows comparable efficacy to existing options, as it targets NTRK gene fusions across various solid tumors. However, the evidence is primarily based on single-arm trials without direct comparisons to standard treatments, leading to uncertainty about its superiority. The committee noted that while tumors with NTRK fusions shrink in response to the drug, longer follow-up is needed to establish its clinical benefit definitively. This strengthens the market access risk assessment and overall reimbursement probability.
Cost effectiveness
The cost-effectiveness estimates for entrectinib are uncertain, with an ICER of £49,358 per QALY gained, which is above the typical threshold for Healthcare acceptance. The committee acknowledged that while entrectinib has potential for cost-effectiveness under certain conditions, the uncertainty in survival estimates and the generalizability of the trial population raise concerns about its economic viability. This informs pricing and reimbursement risk and pharmaceutical reimbursement forecasting.
Quality of life
The document does not provide robust evidence of significant improvements in HRQoL associated with entrectinib. The utility values derived from the STARTRK-2 study may not be generalizable to clinical practice, especially since entrectinib is positioned as a last-line treatment. The committee expressed uncertainty regarding the utility values used in the economic model. These outcomes align with HTA decision predictors and support pricing and reimbursement assessment.
Supporting Domains
Safety and Adverse Effects
Entrectinib has a very good safety profile, with mostly mild or moderate adverse events reported. The committee noted that serious adverse events were rare, indicating that the treatment is generally well-tolerated compared to existing therapies. This profile reduces payer uncertainty and supports access risk forecasting.
Comparator Selection
The clinical trials for entrectinib were single-arm, lacking a direct comparator. The committee concluded that best supportive care was the appropriate comparator, but the absence of a control group in the trials limits the robustness of the evidence regarding its comparative effectiveness. This aligns with HTA comparator analysis and strengthens the market access submission.
Patient Population and Subgroups
The inclusion of both adults and children with NTRK fusion-positive tumors in the trials enhances the generalizability of the findings. However, the small sample sizes and the limited representation of various tumor types introduce some uncertainty regarding the effectiveness across the broader patient population. This enhances reimbursement likelihood rating and payer relevance.
Care Pathway Integration
Entrectinib can be integrated into existing care pathways with minor adjustments, particularly as Healthcare England is establishing a national service for genomic testing. The committee noted that while some infrastructure changes are needed, they are manageable. This supports budget impact analysis and facilitates market access feasibility.
Resource Use and Cost Implications
The economic model includes diagnostic testing costs, which are appropriate given the current clinical practice. However, the committee recognized that the overall resource burden is high, and uncertainties in the economic analysis could necessitate restrictions on use. This supports pricing model stress-testing and payer evidence expectations.
Evidence Quality and Robustness
The evidence base is primarily derived from single-arm trials, which raises concerns about bias and robustness. While the pooled analysis of trials provides some insights, the lack of control groups and the small sample sizes limit the reliability of the conclusions drawn. These outcomes align with HTA decision predictors and support pricing and reimbursement assessment.
Uncertainty, Sensitivity, and Broader Impacts
There is significant uncertainty surrounding the clinical and cost-effectiveness of entrectinib, particularly due to the immature survival data and the generalizability of the trial population. The committee acknowledged that further data collection could help address these uncertainties. These factors elevate access risk forecasting within HTA evaluation frameworks.
